Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Camrelizumab + Docetaxel + S-1 in First-line Metastatic Gastric Cancer
NCT04781686Phase 2Unknown
- Start
- May 2021
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04781686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04781686.